GRAIL and Guardant Health report growth in cancer testing

At the Canaccord Genuity Growth Conference, biotechnology companies GRAIL and Guardant Health reported significant growth in their cancer testing and screening sectors.

GRAIL reported approximately 30% revenue growth and 42% test-volume growth in the first half of the year, completing over 117,000 Galleri multi-cancer early detection tests. The company is expanding its reach through digital health platforms, employers, and physician offices. To reduce ordering friction, GRAIL has integrated with Quest Diagnostics and athenahealth, with plans to integrate with Epic by the end of the year.

Guardant Health highlighted accelerating growth in oncology testing, minimal residual disease (MRD), and colorectal cancer screening. The company’s Guardant360 liquid-biopsy therapy selection test saw more than 30% year-over-year growth, while its MRD business, centered on the Guardant Reveal test, grew by more than 100% year-over-year. Guardant Health also announced plans to launch Guardant Reveal Ultra, a tumor-informed offering, in 2026.